The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • E-health company G Medical (GMV) has gained approval to join a U.S. over-the-counter market
  • The company is now tradable on the OTCQB under the code GMMVF
  • G Medical says it is looking to attract American individual and institutional investors
  • It plans to launch a shareholder engagement program in the U.S. soon
  • G Medical’s share price is up 12.12 per cent at midday trade
  • Shares in the company are now trading for 18 cents each

E-health company G Medical (GMV) has told shareholders it received U.S. approval to join over-the-counter market OTCQB. Company shares can now be traded under the code GMMVF.

On entering the American market, the company will have access to individual and institutional investors across the country.

G Medical detailed this will give it improved access to as its products gain popularity in the U.S. Additionally, it is expected to generate more growth opportunities.

“The company’s product suite is continuing to gain traction with medical organisations and healthcare professionals in the United States,” G Medical’s CEO Dr Yacov Geva said.

A medical smartphone case and a smart patch are two of the group’s popular products.

Dr Yacov outlined in today’s release the company is looking to begin securing American investors as it broadens its footprint in the country.

“An active shareholder engagement program is planned in the USA to ensure out investment attractions and growth prospects are highlighted amongst new investors,” he added.

After announcing the approval to the Australian market, G Medical’s share price is up 12.12 per cent at midday trade.

Shares in the company are now trading for 18 cents each.

gmv by the numbers
More From The Market Online

Adveritas launches TrafficGuard self-serve platform for non-enterprise customers

Adveritas has launched an upgraded, fully automated self-serve TrafficGuard platform for global non-enterprise customers.
AI concept

Coming of age story? Now Canberra has inked an MOU with US AI giant Anthropic

Data centres are nothing new for Australia (just look at NEXTDC (ASX:NXT)), and we’ve all been discussing to death the modern topic

Investors will get interim results from Paradigm’s Phase III study in Q3 of this year

Paradigm Biopharma has officially passed a milestone that gives investors in the company a 'fast-track' path…

1414 Degrees attracts $2.69M to fund global data centre market opportunity

1414 Degrees has raised $2.69 million with the funds to support its entry into the giant…